Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2022 | 2021 | 2020 | 2018 | 2017 | 2014
Number of items: 6.

2022

Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., De Braud, F. G. M., Solomon, B., Tan, D. Shao-Weng, Alonso, G., Wolf, J., Park, K., Goto, K., Soldatenkova, V., Szymczak, S., Barker, S., Puri, T., Lin, A. B., Loong, H. H. F. and Besse, B. (2022). Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC). Ann. Oncol., 33. S. S43 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

2021

Goto, K., Oxnard, G., Tan, Shao-Weng D. S. W., Loong, Ho Fung H., Bauer, T. T., Gainor, J., McCoach, C., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y., Ohe, Y., Horiike, A., Park, K., Huang, X., Olek, E., Subbiah, V, Drilon, A. and Wolf, J. (2021). Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC). Pneumologie, 75. S. S42 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

2020

Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y. -J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., Rosen, E., Shah, M. H., Barlesi, F., Cassier, P. A., Bazhenova, L., De Braud, F., Garralda, E., Velcheti, V., Satouchi, M., Ohashi, K., Pennell, N. A., Reckamp, K. L., Dy, G. K., Wolf, J., Solomon, B., Falchook, G., Ebata, K., Nguyen, M., Nair, B., Zhu, E. Y., Yang, L., Huang, X., Olek, E., Rothenberg, S. M., Goto, K. and Subbiah, V. (2020). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med., 383 (9). S. 813 - 825. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

2018

Griesinger, F., Radke, S., Lueers, A., Deschler-Baier, B., Kimmich, M., Sebastian, M., Schulz, C., Brugger, W., Wiewrodt, R., Pirker, R., Fruh, M., Gautschi, O. and Wolf, J. (2018). Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example. Pneumologie, 72 (11). S. 774 - 782. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

2017

Michels, S., Heydt, C., Deschler-Baier, B., Ruesseler, V., Stratmann, J., Steinhauser, S., Fischer, R., Scheffler, M., Fassunke, J., Kron, A., Griesinger, F., Gautschi, O., Sebastian, M., Hellmich, M., Heukamp, L., Merkelbach-Bruse, S., Bttner, R. and Wolf, J. (2017). Molecular panel sequencing of pre-treatment samples reveals mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients. Oncol. Res. Treat., 40. S. 134 - 135. BASEL: KARGER. ISSN 2296-5262

2014

Gautschi, O., Pall, G., Schultheis, A., Keller, F. Aebersold, Gardizi, M., Heuckmann, J., Merkelbach-Bruse, S., Diebold, J., Wolf, J. and Heukamp, L. (2014). LUNG ADENOCARCINOMA WITH RET FUSION: EARLY EXPERIENCE WITH DIAGNOSIS AND TARGETED THERAPY. J. Thorac. Oncol., 9 (4). S. S38 - 1. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1556-1380

This list was generated on Thu May 2 22:06:45 2024 CEST.